SEC Form 4Coverage since May 26, 2026
$RPRX insider trading
Over the last 12 months, Royalty Pharma insiders reported no purchases and 6 sales totaling $20.0M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $20.0M 6 events
- Events · 12m
- 6 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $RPRX · 12Mvia TradingView
Top insiders · 12m
Hite ChristopherEVP & Chairman, Partnering3× · $15.5M
Urist MarshallEVP, Research & Investments2× · $1.0M
Coyne Terrance P.EVP & CFO1× · $3.5M
All insider trades
6 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 9,099 | $55.88 | $508K | -100% | plan |
| Jun 30, 2026 | Hite ChristopherEVP & Chairman, Partnering · O | ▼ Sale | 30,000 | $56.46 | $1.7M | -42.9% | plan · 2 tranches |
| Jun 30, 2026 | Hite ChristopherEVP & Chairman, Partnering · O | ▼ Sale | 100,000 | $56.52 | $5.7M | -17.9% | plan · 2 tranches · indirect |
| Jun 24, 2026 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 9,098 | $55.18 | $502K | -50% | plan |
| Jun 23, 2026 | Hite ChristopherEVP & Chairman, Partnering · O | ▼ Sale | 150,000 | $54.4 | $8.2M | -21.1% | plan · 2 tranches · indirect |
| May 26, 2026 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 64,399 | $53.98 | $3.5M | -100% | plan · indirect |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RPRX feed.